Content of CD4+ cells expressing CD39/CD73 ectonucleotidases in children with inflammatory bowel diseases

The regulation of TNF inhibitor therapy-associated immune responses in inflammatory bowel diseases (IBD) children remains an urgent problem. study aimed at analyzing the expression CD39/CD73 endonucleotidases by different subsets peripheral blood T cells with IBD including Crohn's disease (n = 34) and ulcerative colitis 33) having received inhibitors comparison conditionally healthy 45). Lymphocyte regulatory (Treg, CD4+CD127lowCD25high), activated (Tact, CD4+CD25+CD127high) Th17 (CD4+CD161+CD3+) were studied flow cytometry. results are presented as medians (Me) quartiles (Q25–Q75). In highest lowest relative counts CD39+ found Treg Tact — 31% (15–38) 4% (1–7), respectively. CD73+ 13% (8–21). CD39 CD73 ratio patients IBD, control group well, depended on particular subset. Treg, was not age-dependent. Patients acute revealed decreased compared (12% (9–23) vs 35% (28–39), respectively; р 10–6). remission increased (31% (27–40) 12% (9–23); 9.4 × 10–5). no significant differences apart from reduced disease. indicate association levels CD4+ phase (acute remission) and, accordingly, anti-TNF regimen efficacy.